All posts by admin

25Feb/14

InterMune's drug delays lung disease progression in trial – Reuters UK


The Almagest

InterMune’s drug delays lung disease progression in trial
Reuters UK
The drug is already approved to treat IPF in Europe and Canada, where it is marketed as Esbriet. It is also approved in Japan, South Korea, China, India, Argentina and Mexico. IPF is an irreversible condition that leads to progressive loss of lung
InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Wall Street Journal

all 9 news articles »